A TERAPIA PSICODÉLICA E O POTENCIAL DA PSILOCIBINA NA PSIQUIATRIA MODERNA
UMA REVISÃO INTEGRATIVA
DOI:
https://doi.org/10.64956/gm-unifacol.v1i3.87Keywords:
Psilocibina, Psicodélicos, Estudos Clínicos, Transtornos Psiquiátricos, Usos TerapêuticosAbstract
Given the limitations of conventional treatments for psychiatric disorders, psychedelic therapy is re-emerging as a very promising area, with the potential use of psilocybin as a new therapeutic approach deserving special mention. To analyze the clinical evidence of psilocybin therapy, an integrative review was conducted following the PRISMA guidelines in the electronic databases SciELO, LILACS, and PubMed, encompassing articles published between 2020 and 2025. After the selection process, 9 studies were included for analysis. The review revealed an expanding research field, with publications in high-impact journals and very promising results. The evidence was favorable for the use of psilocybin in the treatment of Major Depressive Disorder and Refractory Depression. Clinical trials also extend the possibilities of using psilocybin to other clinical conditions, such as anorexia nervosa, bipolar II disorder, obsessive-compulsive disorder, and Parkinson's disease, demonstrating a favorable safety profile. On the other hand, research faces some methodological limitations such as small sample sizes and difficulties in conducting double-blind clinical trials. Taken together, psychedelic therapy represents a paradigm shift that opens avenues for new treatment possibilities in the field of psychiatry.
References
AARONSON, Stephen T. et al. SINGLE-DOSE SYNTHETIC PSILOCYBIN WITH PSYCHOTHERAPY FOR TREATMENT-RESISTANT BIPOLAR TYPE II MAJOR DEPRESSIVE EPISODES. JAMA Psychiatry, v. 81, n. 6, p. 555–562, 2024.
BACK, Anthony L.; FREEMAN-YOUNG, Tiffany K.; MORGAN, Lynn; et al. PSILOCYBIN THERAPY FOR CLINICIANS WITH SYMPTOMS OF DEPRESSION FROM FRONTLINE CARE DURING THE PANDEMIC. JAMA Network Open, v. 7, n. 12, e2449026, 2024.
BRADLEY, Eric R. et al. PSILOCYBIN THERAPY FOR MOOD DYSFUNCTION IN PARKINSON’S DISEASE. Neuropsychopharmacology, p. 1–10, 2025.
DAVIS, Alan K. et al. EFFECTS OF PSILOCYBIN-ASSISTED THERAPY ON MAJOR DEPRESSIVE DISORDER. JAMA Psychiatry, v. 78, n. 5, p. 481–489, 2021.
GOLDBERG, Shahar B. et al. POST-ACUTE PSYCHOLOGICAL EFFECTS OF CLASSICAL SEROTONERGIC PSYCHEDELICS. Psychological Medicine, v. 50, n. 16, p. 2655–2666, 2020.
GOODWIN, Guy M. et al. SINGLE-DOSE PSILOCYBIN FOR A TREATMENT-RESISTANT EPISODE OF MAJOR DEPRESSION. The New England Journal of Medicine, v. 387, n. 18, p. 1637–1648, 2023.
JENSEN, Michael E. et al. PSILOCYBIN-ASSISTED THERAPY FOR REDUCING ALCOHOL INTAKE IN PATIENTS WITH ALCOHOL USE DISORDER. British Medical Journal Open, v. 12, n. 10, e066019, 2022.
LI, Li-Jun et al. PSILOCYBIN FOR MAJOR DEPRESSIVE DISORDER. Frontiers in Psychiatry, 2024. Art. 1416420.
PELLEGRINI, Luca et al. SINGLE-DOSE PSILOCYBIN REDUCES SYMPTOMS IN ADULTS WITH OBSESSIVE-COMPULSIVE DISORDER. Comprehensive Psychiatry, p. 152619, 2025.
RAISON, Charles L. et al. SINGLE-DOSE PSILOCYBIN TREATMENT FOR MAJOR DEPRESSIVE DISORDER. JAMA, v. 330, n. 9, p. 843–853, 2024.
